NASDAQ · NTHIHealthcarePharmaceuticals

NeOnc Technologies Holdings financials

$3.30+4.43%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ2 '26
Jun 30
Q1 '26
Mar 31
Q4 '25
Dec 31
Q3 '25
Sep 30
Q2 '25
Jun 30
Q1 '25
Mar 31
Revenue$0.00$0.00$0.00$0.00$0.00$40.0K
Gross profit$0.00$0.00$0.00$0.00$0.00$40.0K
Gross margin—————100.0%
Operating income-$14.1M-$7.1M-$13.7M-$6.9M-$5.7M-$31.9M
Net income-$14.2M-$8.8M-$15.5M-$8.6M-$5.7M-$32.3M
Net margin—————−80835.2%
Diluted EPS$-0.58$-0.38$-0.73$-0.45$-0.30$-1.78
EBITDA-$14.1M-$7.0M-$13.7M-$6.9M-$5.7M-$31.9M
Operating cash flow-$4.8M-$7.0M-$3.6M-$5.8M-$5.3M-$5.7M
Free cash flow-$4.8M-$7.0M-$4.1M-$5.8M-$5.3M-$5.7M
Diluted shares24.7M23.3M21.2M19.2M19.0M18.1M

Balance sheet

Period endJun 30Mar 31Dec 31Sep 30Jun 30Mar 31
Cash & equivalents$2.0M$138.6K$58.7K$1.5M$125.0K$5.4M
Short-term investments$0.00$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$6.0M$4.7M$0.00$0.00
Total assets$5.2M$3.3M$2.8M$4.1M$3.0M$8.4M
Total liabilities$23.8M$16.6M$20.3M$15.9M$14.8M$18.1M
Shareholders' equity-$18.5M-$13.2M-$17.5M-$11.8M-$11.8M-$9.6M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology